We focused on Arg1 because it is induced in asthma patients and experimental mouse models, can contribute to or suppress Th2-mediated pathology by different mechanisms, and represents a therapeutic target because its enzymatic mechanism is known in great detail, and existing drugs are known inhibitors of arginases in vivo [8], [9]. The gene discussed is ARG1; the disease is asthma.